title: A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).
abstract: Immune responses provoked by human immunodeficiency virus (HIV) infection ultimately are insufficient to control the disease and do not include strong lymphocyte-proliferative responses to HIV antigens or antibodies to many viral epitopes. A randomized double-blind, placebo-controlled trial evaluated the immunogenicity of recombinant HIV envelope vaccine (rgp160) in HIV-infected subjects with > or = 400/mm3 CD4 T cells. Controls received hepatitis B vaccine. Of subjects receiving rgp160, 98% developed lymphocyte-proliferative responses to the immunogen, 33% to a different envelope protein, and 56% and 60% to p24 and p66, respectively. All doses of vaccine (20, 80, 320, 1280 microgram) induced new responses. New antibodies to epitopes on rgp160 developed only in recipients of higher doses of rgp160. CD4 T cell percentages declined less rapidly in recipients of rgp160 than in controls. Vaccination of HIV-infected subjects with rgp160 results in cellular and humoral immune responses to HIV that infection itself had not stimulated.
authors.affiliation: Division of Infectious Diseases and Immunology, New York University Medical Center, USA.
authors.forename: F T
authors.initials: FT
authors.lastname: Valentine
authors.forename: S
authors.initials: S
authors.lastname: Kundu
authors.forename: P A
authors.initials: PA
authors.lastname: Haslett
authors.forename: D
authors.initials: D
authors.lastname: Katzenstein
authors.forename: L
authors.initials: L
authors.lastname: Beckett
authors.forename: C
authors.initials: C
authors.lastname: Spino
authors.forename: M
authors.initials: M
authors.lastname: Borucki
authors.forename: M
authors.initials: M
authors.lastname: Vasquez
authors.forename: G
authors.initials: G
authors.lastname: Smith
authors.forename: J
authors.initials: J
authors.lastname: Korvick
authors.forename: J
authors.initials: J
authors.lastname: Kagan
authors.forename: T C
authors.initials: TC
authors.lastname: Merigan
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D018791:CD4 Lymphocyte Count; D004311:Double-Blind Method; D000939:Epitopes / Q000032:analysis; D015483:HIV Antibodies / Q000097:blood*; D015488:HIV Antigens; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000097:blood; D007376:Interleukin-2 / Q000097:blood; D008213:Lymphocyte Activation / Q000276:immunology*; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D000939:Epitopes; D015483:HIV Antibodies; D015488:HIV Antigens; D007376:Interleukin-2; D014614:Vaccines, Synthetic; C053473:VaxSyn HIV-1 (gp160) vaccine; D007371:Interferon-gamma